Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-i    symbols : NIPNF    save search
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Published: 2021-11-22 (Crawled : 19:00) - biospace.com/
NIPNF | $74.295 -0.01% -52.94% 140 twitter stocktwits trandingview |
Technology Services
 | Email alert Add to watchlist
tg405 positive cancer vaccine
Gainers vs Losers
46% 54%

Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M twitter stocktwits trandingview |
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M twitter stocktwits trandingview |
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M twitter stocktwits trandingview |
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M twitter stocktwits trandingview |

HUBC | $1.95 50.0% 32.99% 73M twitter stocktwits trandingview |
n/a
SPCB | $0.4004 45.07% 31.75% 130M twitter stocktwits trandingview |
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M twitter stocktwits trandingview |
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M twitter stocktwits trandingview |
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M twitter stocktwits trandingview |

EEIQ | $1.16 27.46% 20.86% 6.9K twitter stocktwits trandingview |
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.